Patent intelligence · US
US 10865226
Peptide showing melanogenesis promoting activity and use thereof
Peptide showing melanogenesis promoting activity and use thereof
Patent details — US 10865226
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 15, 2020
- Expiration
- Dec 10, 2040
- Applicant
- CAREGEN CO., LTD.
- Claims
- 20
- CPC classes
- A61K, A61K2800/10, A61K38/00, A61K8/64
Quick answer
US 10865226 (Peptide showing melanogenesis promoting activity and use thereof) is held by CAREGEN CO., LTD.. Status: granted. Granted Dec 15, 2020. Expires Dec 10, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CAREGEN CO., LTD.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K2800/10, A61K38/00, A61K8/64
More from CAREGEN CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 10865226?
US 10865226 (Peptide showing melanogenesis promoting activity and use thereof) is held by CAREGEN CO., LTD.. Status: granted. Granted Dec 15, 2020. Expires Dec 10, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10865226?
CAREGEN CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 10865226 expire?
Our index shows an expiration date of Dec 10, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.